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A B S T R A C T
Maternal alloimmunization to paternally inherited antigens on fetal/neonatal platelets can cause fetal/neonatal
alloimmune thrombocytopenia (FNAIT) after antibody-mediated removal of platelets from the fetal circulation.
The complications vary from mild bleeding symptoms to severe intracranial hemorrhage and subsequent neu-
rological impairment or death. Studies on in vivo mechanisms are challenging to measure directly in pregnant
women, rendering murine models as valuable and attractive alternatives, despite some critical differences be-
tween mice and men affecting the translational value. Here we present and discuss, the different murine models
that substantially have increased our knowledge and understanding of FNAIT pathogenesis – as well as pre-
clinical evaluation of therapeutic and preventive strategies.
1. Introduction
Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a condi-
tion caused by maternal alloimmunization against paternally inherited
platelet antigens on fetal/neonatal platelets, and subsequent antibody-
mediated removal of platelets from the circulation of the fetus or
newborn.
Alloantigens are formed due to allelic variations of glycoprotein
complexes important for hemostasis, by their function as receptors for
fibrinogen, fibronectin, vitronectin, collagen and von Willebrand factor
(vWf). The human platelet antigens (HPA) that may cause alloimmune
complications have been designated into 35 systems (HPA-1 to -35) by
the International Platelet Immunology Nomenclature Committee of the
International Society of Blood Transfusion (ISBT). An updated overview
is available in the HPA database at http://www.versiti.org/HPA.
The GPIIb/IIIa (αIIbβ3 or CD41/CD61) complex is a heterodimeric
αβ integrin (encoded by ITGA2B and ITGB3) that form a receptor for
fibrinogen, fibronectin, vitronectin and vWf, and most of the HPA
systems are present on this complex. Alloimmunization to HPA-1a
cause the vast majority of FNAIT (∼80 %) in Caucasians [1] whereas
antibodies to HPA-4 antigens are more frequently seen in the Asian
population. Other HPA determinants that cause FNAIT are located on
the GPIb-IX-V complex, the GPIa/IIa complex and the CD109 protein on
the platelet surface. In addition, isoantibodies to CD36 in CD36-defi-
cient individuals are also a cause of FNAIT [2,3].
In humans, maternal IgG antibodies are transported across the
placental membranes and into the fetal circulation by Fc receptor-
mediated mechanisms that provides the fetus with humoral protection
during gestation and the first 3–6 months after birth while the en-
dogenous immune system is developing and maturing. This transport of
antibodies has been studied in detail the last decades, and has been
shown to be effectuated by the neonatal Fc receptor (FcRn). This re-
ceptor is not exclusively expressed on human syncytiotrophoblasts in
placental tissue, but importantly also on endothelial cells and in epi-
thelial tissue. FcRn is also crucial for the significantly longer half-life of
IgG compared to the other immunoglobulin classes by pH-dependent
recycling [4]. Even though FNAIT is defined as thrombocytopenia with
or without bleeding in the fetus/newborn, the complications due to
potential harmful effect of the antibodies towards antigen-epitopes
expressed on placental tissue is in the spotlight after observations of low
birthweight in babies of HPA-1a alloimmunized mothers [5]. Today,
there are no licensed drugs for neither prevention nor safe and effective
treatment of FNAIT. However, there is an increasing trend for off-label
use of human intravenous IgG (IVIG) treatment of women with anti-
HPA-1a antibodies, and many clinical guidelines recommend IVIG
treatment of women with a known obstetric history of severe FNAIT
with intracranial hemorrhage (ICH) [6].
Knowledge about genetic and molecular basis, pathogenesis and
prevalence of FNAIT has greatly improved the last 30 years, both due to
the improved repertoire of laboratory analyses, and a number of
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retrospective and prospective human studies. However, studies on in
vivo mechanisms are challenging to measure directly in pregnant
women and fetuses, rendering murine models as valuable and attractive
alternatives. To date, several different models have been used for
studying FNAIT. Here, we present and discuss the insights previous and
current models have given.
2. Similarities and differences - man versus mice relevant for
FNAIT
In order to translate results from murine experiments to the human
setting, the differences between several facets of FNAIT biology should
be carefully acknowledged. These factors include differences in hema-
tology, pregnancy-related anatomy, and immunization: antigen source,
antigen presentation and immune cell interactions, but also antibody-
related factors as transplacental transfer, platelet opsonization and re-
moval as well as effect on endothelial cells in the vascular system and
bleedings.
2.1. Human versus murine platelets and platelet integrins
The murine platelets are smaller and their life-span of 3–4 days is
markedly shorter than the 8–12 days in humans [7]. Platelet counts in
inbred mice, show variations between strains, age and gender, with
reports of normal counts in the range of 600−1500 × 103/μL, with
most commonly reported platelet count in the range of 900−1200 ×
103/μL [8–12]. The platelet count in pups is roughly doubling from day
of delivery (∼400−600 × 103/μL) during the first two weeks of life, to
adult levels within 8 weeks [9]. Thus, the baseline platelet count should
be determined carefully for every model, keeping in mind that there are
also variations in the observed platelet counts due to differences in
sampling techniques (sampling point, sampling method, platelet acti-
vation and clotting) and quantitation methods (manual counting, au-
tomatic analyzers or flow cytometry) [10,11]. Severity of thrombocy-
topenia in or between FNAIT models based on platelet counts alone
should be compared with caution.
Platelet integrin complexes function as receptors for hemostatic
factors important for platelet function and hemostasis in mice as in
humans. Amino acid sequence identity between human and murine
platelet integrins are generally more than 80 % for the mature proteins
(not including the signal peptide, based on NCBI reference sequences):
0.91 for GPIIIa (ITGB3), 0.80 for GPIIb (ITGA2B), 0.93 for GPIbα
(ITGB1) and 0.83 for GPIa (ITGA2) in line with original characteriza-
tions [13,14]. High amino acid sequence identity score may however,
not necessarily represent epitope homology – depending on the con-
formational nature of the given epitope. Since there are no reports of
alloantigenic platelet integrin variants between the inbred strains, im-
munogenicity is created either by knockout of murine glycoprotein
genes or by using human platelets. Human anti-HPA-1a antisera do not
bind the murine wild-type GPIIIa, which otherwise would have pre-
cluded all use with such antibodies with the mouse as a host [15]. Thus,
for studies of antibodies reactive with the human GPIIIa (their re-
activity patterns, in vivo effect and treatment potential), chimeric
models, recombinant proteins, or murine platelets, with reconstructed
human epitopes are required.
2.2. Human versus murine placenta and placental transport
The placenta is of high evolutionary diversity among species, and
for some research areas (placental disease/toxicology studies), the
murine placenta has been demonstrated to have less translational value
due to its differences in major key factors for placentation and placental
function, reviewed by Schmidt et al. [16].
In mice, the pups are growing in multiple embryonic sacs in each of
the two uterine branches, where each embryonic sac contains a single
pup and its own placenta. Importantly, for models of alloimmunization,
both the human and mouse have discoidal, hemochorial placentas
where maternal blood are in direct contact with the trophoblast cells (of
fetal origin). Maternal immune cells may interact with fetal antigens
expressed on the outer cell layer in the intravillous space in humans,
which correspond to the structurally different placental labyrinth in
mice [16]. In addition to the chorioallantoic placenta, the mouse also
has a secondary placental structure - the inverted yolk sac - that sur-
rounds the fetus throughout gestation, and is the structure that allows
transfer of maternal antibodies to the fetus by transcytosis by the FcRn
in the inner layer of the inverted yolk sac structure [17]. Thus, trans-
placental transport of antibodies is mediated by anatomically different
structures in humans and mice, while facilitated by the same receptor.
3. Mouse models in FNAIT – Insights from different models
Different mice strains demonstrate diverse immune responses due to
variations in genetic background [18,19]. Alloantigens, that in most
cases differ from self by a single amino acid residue substitution, have a
limited number of antigenic peptides to be presented in MHC class II,
compared to other foreign substances as microbes, parasites and
viruses. Therefore, differences in antigen-presenting capacity due to
different MHC haplotypes may affect immunization in this setting. In
addition, it should be kept in mind that the uniformity within the
mouse colony due to genetic identity within an inbred mice strain,
dramatically changes whenever an antigen-specific immune response is
mounted by the adaptive immune cells, due to its nature of random
sequence generation – affecting the potency, titer and polyclonality of
antibody repertoire.
The choice of mouse strain or design of knockout models may sig-
nificantly influence the results of the study, as their intrinsic phenotype
may affect their overall health, relevant hematology, immune responses
and breeding.
3.1. Murine model designs
In 2006, Ni and colleagues presented a model of GPIIIa knockout
(β3−/−) mice backcrossed onto a BALB/c background [20]. The original
β3-deficient mouse strain was designed by Richard O. Hynes and his
group to study Glanzmann thrombasthenia [21], and due to its suitability
to study platelet conditions it was utilized to generate the first murine
model of FNAIT [20]. Use of a corresponding GPIbα-knockout model,
originally made to study Bernard-Soulier syndrome [22], was also re-
ported by Li and colleagues [23]. In these two models, alloimmunization
(or rather isoimmunization) is achieved by repeated injection of wild-type
platelets, and pre-immunized females are bred with wild-type males to
assess the effect of the antibodies on pregnancy and pups. Platelet gly-
coprotein-deficient mice are however phenotypically affected: GPIIIa-
deficient mice have higher fetal/neonatal mortality rate due to placental
defects, anemia and hemorrhages, and by design impaired platelet func-
tion [21], whereas GPIbα-deficient mice have reduced platelet count and
reduced platelet function [22]. A chimeric model expressing human
GPIIIa (originally used to study Glanzmann thrombasthenia [24]) allows
studies on human anti-GPIIIa antibodies in a murine system [25].
For other studies, non-obese diabetic/severe combined im-
munodeficient (NOD/SCID) or SCID mice has been used. These mice
harbor the SCID mutations leading to mice without functional B and T
cells and the NOD mutations leading to mice without 1) functional
natural killer (NK) cells, 2) functional antigen-presenting cells and 3)
circulating complement; the mice will be affected in many ways [26]. In
this model, the mice functions as a host, injected with human material
(antigen and antibodies), but may nevertheless depend on immune-
related effects like Fcγ receptor-mediated functions. The knowledge
acquired from all these models, with respect to treatment, prevention
and pathogenesis is discussed below.
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3.2. Studies on therapeutic strategies
3.2.1. Therapeutic administration of IVIG to treat FNAIT
In the GPIIIa knockout model, repeated injections of wild-type
platelets into β3−/− mice gave robust and potent generation of β3
integrin-specific antibodies, which subsequently caused thrombocyto-
penia when injected into wild-type mice [20]. The titer of maternal
antibody against β3 integrin correlated with the severity of FNAIT in
the pups, in pre-immunized females bred with wild-type males. High
antibody titer caused severe FNAIT with signs of bleeding, ICH, and in
the most severe cases miscarriage and increased mortality rate [20].
This model, resembling human anti-GPIIIa-mediated FNAIT conditions,
allows studies of the pathogenic mechanisms as well as studies at-
tempting to interfere with pathogenesis. IVIG is licensed for use to treat
a number of immune-deficient conditions, but is also used to treat au-
toimmune diseases. Human IVIG has also been used in mouse models of
immune thrombocytopenia (ITP) [27]. By applying this strategy to the
above FNAIT model, it was shown that administration of IVIG in pre-
immunized β3−/− mice (bred with male wild-type mice) during preg-
nancy, increased platelet counts of the newborn pups, and more im-
portantly, bleeding symptoms, pup mortality and number of mis-
carriages were diminished [20]. The therapeutic effect of IVIG was
further confirmed in a number of other, subsequent studies mentioned
below.
3.2.2. FcRn – a potential therapeutic target
The transplacental transport of maternal antibodies is a central part
of human FNAIT pathogenesis. In 2010, Ni and colleagues reported
another mouse model, generated through the combination of β3-defi-
cient mice and FcRn-deficient mice, creating β3−/−FcRn−/−
mice [28]. By pre-immunizing and breeding deficient and wild-type β3/
FcRn mice in different combinations, they showed that also in this
murine model, fetal rather than maternal FcRn, is crucial for trans-
portation of antibodies across the placenta and thus, critical for the
development of FNAIT. When pre-immunized β3−/−FcRn−/− females
were bred with β3−/−FcRn−/− males, no FNAIT occurred in the pups
even though anti-β3 antibodies were present in the mother. However,
by treating these pregnant mice with IVIG, there was a decrease in
antibody titer in the mothers, showing that IVIG also may function
through FcRn-independent pathways [28]. In the light these results,
they targeted this receptor to reduce harmful effect of anti-β3 anti-
bodies, as had previously been done in animal models of autoimmune
conditions [29]. Indeed, they were able to show that by injecting an
anti-FcRn antibody into pregnant pre-immunized β3+/+FcRn+/+ (bred
with wild-type males; β3+/+FcRn+/+) the newborn pups had normal
platelet counts and showed no abnormalities. Less severe thrombocy-
topenia was also seen in pups when treating pregnant pre-immunized
β3−/−FcRn−/− mice (bred with wild-type males) with anti-FcRn an-
tibody [28]. As the authors pointed out, the monoclonal anti-FcRn
antibody could be administrated with good effect in lower doses than
IVIG. Thus, an anti-FcRn antibody could be an attractive alternative to
IVIG which is a plasma-derived product of limited source, has batch-to-
batch variations, and has adverse effects when administered in high
dose.
Noteworthy, when comparing FcRn between species, human FcRn
shows immense restrictions when binding to IgG from different species
with no or very low binding to murine IgG, while murine FcRn binds
human IgG better than murine IgG [30]. Andersen and colleagues also
confirmed this in an in vitro experiment using soluble recombinant
murine and human FcRn binding to IgG1 [31]. These cross-species
differences may affect the experimental results of half-life and trans-
placental transfer analyses as well as potential mechanistic artifacts in
the model [32]. Several anti-FcRn antibodies are in the drug develop-
ment pipeline for autoimmune and alloimmune conditions. Of utmost
relevance to FNAIT, the M281, a human anti-FcRn antibody has been
demonstrated to efficiently reduce transplacental transport of IgG in a
human ex vivo placental perfusion model [33]. This molecule is cur-
rently in clinical phase trials as a potential treatment for the alloim-
mune complication hemolytic disease of fetus and newborn [34,35].
3.2.3. FNAIT treatment by prevention of fetal platelet destruction
A chimeric mouse model expressing a hybrid complex of murine
αIIb/human β3 [24] was used by Ghevaert and colleagues to examine
the ability of the recombinant IgG1 antibody B2G1 (HPA-1a-specific
mAb) to prevent platelet destruction [25]. Using bone marrow from β3-
deficient mice [21], they transduced it with a lentivirus vector con-
taining cDNA of the human ITGB3 comprising either HPA-1a or 1b, and
next, the bone marrow was transplanted into lethally irradiated β3-
deficient mice [24,25]. Interestingly, F(abʹ)2 B2G1 antibody fragments
was used as a proof of principle for the effect of non-FcγR-binding re-
agents to inhibit and prevent platelet destruction by intact B2G1 anti-
body or polyclonal anti-HPA-1a sera in the chimeric mouse model [25].
Consequently, a modified B2G1 variant without FcγR-binding can have
platelet protective effects and thus potentially be a candidate for FNAIT
treatment, given proper FcRn-binding for transport to the fetus.
Another mouse model was presented in 2009 by Bakchoul and
colleagues, in an FNAIT study focusing on platelet clearance in NOD/
SCID mice (JAX stock #001303) [36]. This immunodeficient mouse
model does not have functional lymphoid cells and have no or low le-
vels of immunoglobulin making the model ideal for graft studies [26]
but also antibody-mediated platelet clearance studies [37]. The injec-
tion of maternally derived human anti-HPA-1a IgG after supplying
NOD/SCID mice with resting human platelets from HPA-1ab donors,
mediated clearance of these platelets in vivo [36]. By introducing a
monoclonal murine antibody (mAb SZ21, F(abʹ)2) directly after platelet
transfusion, the platelet clearance by human anti-HPA-1a antibodies
was efficiently inhibited. Importantly, this study confirmed the poten-
tial to treat FNAIT using agents that block the binding of the maternally
derived antibodies to the HPA-1a epitope [36]. The SZ21 antibody was
later deglycosylated by Bakchoul and colleagues and injected into
pregnant BALB/c mice, where it was transferred to the fetus to the same
degree as native SZ21, and still blocked the binding of maternal anti-
bodies to the HPA-1a epitope [38]. As deglycosylation of IgG antibodies
is well known to terminate Fc receptor-binding and thus Fc-related
effector functions [39], it could make the antibody suitable for treat-
ment [38]. Thus, this study supports that deglycosylated monoclonal
antibodies could be a potential FNAIT treatment in the future.
3.2.4. Potential therapeutic targeting of T cells by peptides
There has also been interest in targeting the T cell response in
FNAIT, as the peptide harboring the HPA-1a epitope (the Leu33 re-
sidue) is efficiently presented to HPA-1a-specific T cells by antigen-
presenting cells expressing the DRA/DRB3*01:01 molecule [40–46].
Jackson and colleagues made attempts to dampen already established
immune responses by tolerization with peptide treatment [47]. In a
SCID mice model depleted of NK cells and macrophages, PBMC from
HLA-DRB3*01:01-positive HPA-1a alloimmunized women were in-
traperitoneally injected followed by administration of HPA-1a-derived
peptides. After 2 and 3 weeks, HPA-1a+ platelets were injected to boost
any present response against the antigen. However, in this system, no
consistent effect of this regimen was seen, measured by anti-HPA-1a
antibody responses in vivo [47]. This kind of therapeutic strategy still
holds potential, but may require additional factors targeting the an-
tigen-presenting cells, other than peptide alone, to induce an effective
tolerogenic effect on T cells [48].
3.3. Potential prevention of alloimmuniztion
While many studies are designed to study treatments of FNAIT, the
notion that immunization often takes place in connection with delivery
[49], opened the possibility to employ the prophylactic strategy that
has successfully reduced the incidence of RhD alloimmunizations. The
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administration of human plasma-derived anti-D antibody treatment is
based on the concept of antibody-mediated immune suppression
(AMIS). Still it is unclear exactly how passively injected antibodies
suppress the immune system, but different mechanisms are proposed, as
discussed by Kumpel and Elson [50]. Briefly, this includes inhibition of B
cells through crosslinking of the B-cell receptor and the inhibitory re-
ceptor FcγRIIB on B cells with the antibody-antigen complex, or clearance
of antigens, where the antigen is removed from the circulation before the
antigen is seen and processed by the immune system [51]. However,
Bernardo and colleagues could induce AMIS in knockout mice for either
activating or inhibitory Fcγ receptors [52]. AMIS was similarly induced in
these models when using antibodies lacking their Fc region indicating
that AMIS also works through Fc and Fcγ receptor-independent pathways
[52]. In addition, antibody masking of the epitope that blocks the re-
cognition of antigen by B-cell receptors has been suggested as another
possibility. However, based on stoichiometric calculations only a small
portion of the RhD epitopes would be masked [50].
In investigation of the potential prophylactic approach, Tiller and
colleagues managed to induce AMIS by injection of mouse anti-β3 an-
tisera subsequent to transfusion of murine wild-type platelets into β3−/
− mice [53]. Importantly, AMIS was also seen using human anti-HPA-
1a antibodies or the monoclonal murine antibody SZ21 after transfu-
sion of human HPA-1a+ platelets [53]. Thus, the findings from this
study supported the concept that also FNAIT may be prevented through
a prophylactic regimen.
3.4. Insights into pathogenesis from murine models
3.4.1. Anti-GPIbα-antibodies may cause miscarriages through reduced
placental function
Although the majority of FNAIT complications are due to αIIbβ3 in-
compatibilities, there are also cases reported due to alloantibodies against
GPIbα [1]. By making a GPIbα knockout mouse model similar to the
GPIIIa knockout, Li and colleagues showed that pre-immunized GPIbα-
deficient female mice have an very high miscarriage rate when bred with
wild-type mice compared to the β3-deficient mouse model [23]. The
miscarriages were accompanied by reduced placental function and de-
velopment, while treatment with either anti-FcRn antibodies or IVIG
successfully increased the number of live pups. This study suggests that
there might be many unreported FNAIT incidents due to frequent mis-
carriages caused by antibodies against glycoprotein GPIbα, which then
masks the severity of this condition. Nevertheless, this study also supports
the use of IVIG or antibodies against FcRn as FNAIT treatment [23].
In a follow-up study, it was shown that immunogenicity of GPIbα is
lower than for GPIIIa in these knockout models, as more wild-type
platelets were required for potent antibody responses in immunization
experiments [54]. Mounting an efficient antibody response to foreign
structures generally depends on activation of dendritic cells and in-
duction of a pro-inflammatory environment, by binding of pattern re-
cognition receptors to microbe-specific structures and/or endogenous
stress signals. Allogenic proteins, such as blood type antigens and pla-
telet glycoproteins will most likely not activate the innate immune cells
by their sole presence in circulation. It was previously reported that
ongoing authentic infection, or the mimicking of inflammation with
Poly I:C can induce or enhance antibody responses in RBC-alloimmu-
nization models [55]. Accordingly, injection of LPS or Poly I:C
(mimicking bacterial or viral infections, respectively) both enhanced
antibody production and subsequent miscarriages in the knockout
mice [54]. This is adding a piece to the puzzle that factors like in-
flammation may influence immunization and the quality and quantity
of the alloreactive response. Whether the timing of the inflammation
signals are critical for immunization to platelet antigens, as was in-
dicated in a mouse model where the timing of Toll-like receptor 3-in-
duced inflammation and exposure to RBC antigens affects the degree of
alloimmunization [56], is not yet known.
3.4.2. Intracranial hemorrhage might be caused by impaired angiogenesis
The last decades, the focus of FNAIT treatment has been on im-
proving the platelet count of the fetus or neonate, but in a recent study
by Yougbaré and colleagues, they highlight that β3 integrin has an
important role in angiogenesis in relation to development of the fetus
[57]. Here, they showed that it might not be thrombocytopenia that
causes ICH, but rather the maternal anti-β3 antibodies that impair an-
giogenesis leading to ICH in the fetus. In the β3-deficient mouse model,
anti-β3 antibodies impaired the vessel density in the brain and retina of
the delivered pups, also accompanied by increased endothelial cell
apoptosis and inhibited angiogenic signaling. Importantly, anti-HPA-1a
antibodies of anti-αvβ3 specificity in development of FNAIT-associated
ICH, mediated through binding to endothelial cells, have also been
reported [58]. As shown previously [20,23,28], IVIG can be used to
ameliorate FNAIT, but in this study they also saw improvement of
vascular density and less apoptosis [57]. These findings indicate that
treatment of FNAIT preferentially should be focused on eliminating the
maternal anti-β3 antibodies rather than increasing the platelet count of
the fetus. Another study using the β3-deficient mouse model recently
found that activated NK cells causes apoptosis of β3 integrin-positive
trophoblasts in the placenta, which subsequently leads to placental
dysfunction and miscarriages [59]. By depleting the NK cells or through
functional blockage of the NK receptors FcγRIIIa or NKp46, both pla-
cental growth restriction and miscarriage were reduced [59]. This study
introduces another alternative approach to treat FNAIT, but in addition,
it also sheds light on the pathological mechanisms in the development
of FNAIT.
3.4.3. Clinical significance of low-avidity anti-platelet antibodies
Bakchoul and colleagues used the NOD/SCID model to show that
low-avidity anti-HPA-1a antibodies from a series of FNAIT cases cleared
human platelets from HPA-1ab donors in vivo - even though these an-
tibodies may not be detected in standard serological and solid-phase
glycoprotein-specific assays [60]. Such antibodies can be detected by
surface plasmon resonance (SPR) measurements which allows increased
sensitivity in part by eliminating the washing steps used in conven-
tional methods [60].
Peterson and colleagues later confirmed (using the NOD/SCID mice
model) that low-avidity antibodies can cause FNAIT and that many cases
go undetected [61]. In this study, most women that had low-avidity an-
tibodies only, were HLA-DRB3*01:01-negative suggesting that these
women have a predisposition to generate such antibodies [61]. Tenta-
tively, this could be due to a less efficient underlying T cell response
supporting potent antibody responses, as several reports support the role
of HLA-DRB3*01:01 in HPA-1a antigen presentation [40–45] and clinical
outcome [46,62].
3.4.4. Using the murine system to study the antigenic epitopes for antibodies
Comparative analyses to study antibody reactivity have used human
and murine recombinant proteins. Based on amino acid sequence
comparisons, residues important for anti-HPA-1a antibody binding was
determined two decades ago [15]. Since then, detailed characteriza-
tions of the glycoprotein complex and conformation important for an-
tibody binding have been resolved by crystal structures and experi-
ments with site-directed mutagenesis variants [63–65]. However, due
to recent CRISPR/Cas9 technology for site-directed mutagenesis in the
murine genome, mouse platelets are now valuable again: designed,
humanized murine platelets to map the epitope for different anti-HPA-
1a monoclonal antibodies [66].
4. Conclusions and future perspectives
Important insights into the pathogenesis, treatment and prevention
of FNAIT have been given by the elegant studies on knockout mice
models. An advantage with knockout models is that injections with
wild-type antigen causes immunization against the entire native
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protein, likely representing a more general strategy, not restricting the
translational value to a single alloantigen system. However, from a
molecular interaction point of view, the glycoprotein knockout models
unfortunately lack the essential fine-tuned balance of reactivity of self
and non-self, both regarding conformational epitopes for antibody-
specificity and for peptide-antigen presentation and recognition by
antigen-specific T cells. Most antibodies causing FNAIT are thought to
be specific to a single epitope, at least caused by a single amino acid
substitution. Thus, the study of preventive or therapeutic treatments
using monoclonal antibodies could be more challenging to examine in
knockout mice. Models that take these factors into account, would
better mimic the epitope-specific responses in future studies, as im-
proved strategies are needed for diagnosis and treatment of women
with a potential high risk of FNAIT in their newborns.
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